Immunology in schizophrenic disorders;Immunologische aspekte bei schizophrenen störungen

Nervenarzt

Volumn 78, Issue 3, 2007, Pages 253-263

  Muller N ^a   Schwarz, M J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Immunology; Inflammation; N methyl D aspartate; Psychoneuroimmunology; Schizophrenia

Indexed keywords

CHOLINERGIC RECEPTOR; CYCLOOXYGENASE 2 INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE;

ASTROCYTE; CATALYSIS; COGNITION; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); DOPAMINERGIC SYSTEM; ENZYME INHIBITION; GENETICS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGY; INTRAUTERINE INFECTION; METABOLISM; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROTRANSMISSION; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SENSITIZATION;

BRAIN; CYTOKINES; ENCEPHALITIS; HUMANS; INFLAMMATION; MODELS, IMMUNOLOGICAL; MODELS, NEUROLOGICAL; MODELS, PSYCHOLOGICAL; PSYCHONEUROIMMUNOLOGY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33847714348     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-006-2108-9     Document Type: Review

References (86)

1. Aloisi F, Ria F, Adorini L (2000) Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 21:141-147
2. Aloisi F, Serafini B, Adorini L (2000) Glia-T cell dialogue. J Neuroimmunol 107:111-117
3. Bayer TA, Buslei R, Havas L et al. (1999) Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 20:126-128
4. Bechter K, Schreiner V, Herzog S et al. (2003) [CSF filtration as experimental therapy in therapyresistant psychoses in Borna disease virus-seropositive patients]. Psychiatr Prax 30:216-220
5. Brown AS, Begg MD, Gravenstein S et al. (2004) Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 61:774-780
6. Brown AS, Hooton J, Schaefer CA et al. (2004) Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 161:889-895
7. Carlsson A (1998) Schizophrenie und Neurotransmitterstörungen. Neue Perspektiven und therapeutische Ansätze. In: Möller H-J, Müller N (Hrsg) Schizophrenie - Moderne Konzepte zu Diagnostik, Pathogenese und Therapie. Springer, Berlin Heidelberg New York, S 93-116
8. Casolini P, Catalani A, Zuena AR et al. (2002) Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 68:337-343
9. Cazzullo CL, Scarone S, Grassi B et al. (1998) Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry 22:947-957
10. Chiang SSW, Riedel M, Müller N et al. (2004) Th2-shift in schizophrenia: primary findings from whole blood in vitro stimulation. Psychiatry Online
11. Das I, Khan NS (1998) Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglandins Leukot Essent Fatty Acids 58:165-168
12. Dean B (2003) The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J Neurochem 85:1-13
13. Dean K, Murray RM (2005) Environmental risk factors for psychosis. Dialogues Clin Neurosci 7:69-80
14. Erhardt S, Oberg H, Mathe JM et al. (2001) Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 20:353-362
15. Erhardt S, Schwieler L, Engberg G (2003) Kynurenic acid and schizophrenia. Adv Exp Med Biol 527:155-165
16. Farber NB, Wozniak DF, Price MT et al. (1995) Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol Psychiatry 38:788-796
17. Fortier ME, Joober R, Luheshi GN et al. (2004) Maternal exposure to bacterial endotoxin during pregnancy enhances amphetamine-induced locomotion and startle responses in adult rat offspring. J Psychiatr Res 38:335-345
18. Furukawa H, del RA, Monge-Arditi G et al. (1998) Interleukin-1, but not stress, stimulates glucocorticoid output during early postnatal life in mice. Ann N Y Acad Sci 840:117-122
19. Gattaz WF, Abrahao AL, Foccacia R (2004) Childhood meningitis, brain maturation and the risk of psychosis. Eur Arch Psychiatry Clin Neurosci 254:23-26
20. Grohmann U, Fallarino F, Puccetti P (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24:242-248
21. Grosskopf A, Müller N, Malo A et al. (1998) Potential role for the narcolepsy- and multiple sclerosis-associated HLA allele DQB1*0602 in schizophrenia subtypes. Schizophr Res 30:187-189
22. Guillemin GJ, Kerr SJ, Smythe GA et al. (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78:842-853
23. Harris SG, Padilla J, Koumas L et al. (2002) Prostaglandins as modulators of immunity. Trends Immunol 23:144-150
24. Heyes MP, Chen CY, Major EO et al. (1997) Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 326:351-356
25. Hilmas C, Pereira EF, Alkondon M et al. (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463-7473
26. Kaiya H, Uematsu M, Ofuji M et al. (1989) Elevated plasma prostaglandin E2 levels in schizophrenia. J Neural Transm 77:39-46
27. van Kammen DP, McAllister-Sistilli CG, Kelley ME (1997) Relationship between immune and behavioral measures in schizophrenia. In: Wieselmann G (ed) Current update in psychoimmunology. Springer, Berlin Heidelberg New York, pp 51-55
28. Kessler M, Terramani T, Lynch G et al. (1989) A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319-1328
29. Kim JS, Kornhuber HH, Schmid-Burgk W et al. (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20:379-382
30. Kiss C, Ceresoli-Borroni G, Guidetti P et al. (2003) Kynurenate production by cultured human astrocytes. J Neural Transm 110:1-14
31. Körschenhausen DA, Hampel HJ, Ackenheil M et al. (1996) Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr Res 19:103-109
32. Kraepelin E (1919) Dementia Praecox. Churchill Livingston, New York
33. Krystal JH, Karper LP, Seibyl JP et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
34. Laruelle M, Abi-Dargham A, van Dyck CH et al. (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 20:9235-9240
35. Lee H, Baek S, Joe SJ et al. (2006) Modulation of IFN-gamma production by TNF-alpha in macrophages from the tumor environment: significance as an angiogenic switch. Int Immunopharmacol 6:71-78
36. Leweke FM, Gerth CW, Koethe D et al. (2004) Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:4-8
37. Maier W, Hofgen B, Zobel A et al. (2005) Genetic models of schizophrenia and bipolar disorder: overlapping inheritance or discrete genotypes? Eur Arch Psychiatry Clin Neurosci 255:159-166
38. Meira-Lima IV, Pereira AC, Mota GF et al. (2003) Analysis of a polymorphism in the promoter region of the tumor necrosis factor alpha gene in schizophrenia and bipolar disorder: further support for an association with schizophrenia. Mol Psychiatry 8:718-720
39. Miller CL, Llenos IC, Dulay JR et al. (2004) Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 15:618-629
40. Mittleman BB, Castellanos FX, Jacobsen LK et al. (1997) Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 159:2994-2999
41. Molholm HB (1942) Hyposensitivity to foreign protein in schizophrenic patients. Psychiatr Q 16:565-571
42. Müller N (1997) Die Rolle des Zytokinnetzwerks im ZNS und psychische Störungen. Nervenarzt 68:11-20
43. Müller N (2004) Immunological and infectious aspects of schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:1-3
44. Müller N, Schwarz MJ (2003) Role of the cytokine network in major psychoses. In: Hertz L (ed) Nonneuronal cells of the nervous system: function and dysfunction. Elsevier, Amsterdam, pp 999-1031
45. Müller N, Ackenheil M, Hofschuster E et al. (1991) Cellular immunity in schizophrenic patients before and during neuroleptic treatment. Psychiatry Res 37:147-160
46. Müller N, Riedel M, Schwarz MJ et al. (1997) Immunomodulatory effects of neuroleptics to the cytokine system and the cellular immune system in schizophrenia. In: Wieselmann G (ed) Current update in psychoimmunology. Springer, Berlin Heidelberg New York, pp 57-67
47. Müller N, Empl M, Riedel M et al. (1997) Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 247:308-313
48. Müller N, Riedel M, Hadjamu M et al. (1999) Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiatry 156:634-636
49. Müller N, Riedel M, Ackenheil M et al. (2000) Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World J Biol Psychiatry 1:173-179
50. Müller N, Riedel M, Scheppach C et al. (2002) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159:1029-1034
51. Müller N, Ulmschneider M, Scheppach C et al. (2004) COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 254:14-22
52. Müller N, Riedel M, Schwarz MJ (2004) Psychotropic effects of COX-2 inhibitors - a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 37:266-269
53. Müller N, Riedel M, Schwarz MJ et al. (2005) Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 255:149-151
54. Nuechterlein KH, Dawson ME, Green MF (1994) Information-processing abnormalities as neuropsychological vulnerability indicators for schizophrenia. Acta Psychiatr Scand Suppl 384:71-79
55. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007
56. Ozawa K, Hashimoto K, Kishimoto T et al. (2006) Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 59:546-554
57. Pilowsky LS, Bressan RA, Stone JM et al. (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 11:118-119
58. Pyeon D, Diaz FJ, Splitter GA (2000) Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. J Virol 74:5740-5745
59. Ramchand R, Wei J, Ramchand CN et al. (1994) Increased serum IgE in schizophrenic patients who responded poorly to neuroleptic treatment. Life Sci 54:1579-1584
60. Rantakallio P, Jones P, Moring J et al. (1997) Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: a 28-year follow-up. Int J Epidemiol 26:837-843
61. Riedel M, Krönig H, Schwarz MJ et al. (2002) No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. Eur Arch Psychiatry Clin Neurosci 252:232-234
62. Riedel M, Spellmann I, Schwarz MJ et al. (2006) Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res (in press). DOI 10.1016/j.jpsychires.2005.11.007
63. Rothermundt M, Falkai P, Ponath G et al. (2004) Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 9:897-899
64. Rothermundt M, Ponath G, Arolt V (2004) S100B in schizophrenic psychosis. Int Rev Neurobiol 59:445-470
65. Rowe J, Yerkovich ST, Richmond P et al. (2005) Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect Immun 73:8130-8135
66. Schuld A, Hinze-Selch D, Pollmacher T (2004) Zytokinnetzwerke bei Patienten mit Schizophrenie und ihre Bedeutung für die Pathophysiologie der Erkrankung. Nervenarzt 75:215-226
67. Schwab SG, Mondabon S, Knapp M et al. (2003) Association of tumor necrosis factor alpha gene - G308A polymorphism with schizophrenia. Schizophr Res 65:19-25
68. Schwarcz R, Pellicciari R (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303:1-10
69. Schwarcz R, Rassoulpour A, Wu HQ et al. (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521-530
70. Schwarz MJ, Riedel M, Ackenheil M et al. (2000) Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol Psychiatry 47:29-33
71. Schwarz MJ, Chiang S, Müller N et al. (2001) T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 15:340-370
72. Schwarz MJ, Krönig H, Riedel M et al. (2005) IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci 256:72-76
73. Schwieler L, Erhardt S, Erhardt C et al. (2005) Prostaglandin-mediated control of rat brain kynurenic acid synthesis - opposite actions by COX-1 and COX-2 isoforms. J Neural Transm 112:863-872
74. Speciale C, Wu HQ, Cini M et al. (1996) (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol 315:263-267
75. Sperner-Unterweger B, Miller C, Holzner B et al. (1999) Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients. In: Müller N (ed) Psychiatry, psychoimmunology, and viruses. Springer, Berlin Heidelberg New York, pp 115-119
76. Stolina M, Sharma S, Lin Y et al. (2000) Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164:361-370
77. Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309-379
78. Sumiyoshi T, Jin D, Jayathilake K et al. (2005) Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. Int J Neuropsychopharmacol 8:451-455
79. Takikawa O, Yoshida R, Kido R et al. (1986) Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J Biol Chem 261:3648-3653
80. Tamminga CA, Cascella N, Fakouhl TD et al. (1992) Enhancement of NMDA-mediated transmission in schizophrenia: effects of milacemide. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 171-177
81. Tanaka KF, Shintani F, Fujii Y et al. (2000) Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Res 96:75-80
82. Tohmi M, Tsuda N, Watanabe Y et al. (2004) Perinatal inflammatory cytokine challenge results in distinct neurobehavioral alterations in rats: implication in psychiatric disorders of developmental origin. Neurosci Res 50:67-75
83. Wierzba-Bobrowicz T, Lewandowska E, Kosno-Kruszewska E et al. (2004) Degeneration of microglial cells in frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol 42:157-165
84. Wilke I, Arolt V, Rothermundt M et al. (1996) Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246:279-284
85. Yolken RH, Torrey EF (1995) Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 8:131-145
86. Zobel A, Maier W (2004) Endophänotypen - ein neues Konzept zur biologischen Charakterisierung psychischer Störungen [Endophenotype - a new concept for biological characterization of psychiatric disorders]. Nervenarzt 75:205-214